[{"id":"39a324bd-88d1-474f-bca1-4422352c8314","acronym":"","url":"https://clinicaltrials.gov/study/NCT04629846","created_at":"2021-01-19T20:36:16.742Z","updated_at":"2025-02-25T13:53:31.160Z","phase":"Phase 3","brief_title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.","source_id_and_acronym":"NCT04629846","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • Ansaizhu (pertuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 517","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 08/22/2022","primary_completion_date":" 08/22/2022","study_txt":" Completion: 10/24/2023","study_completion_date":" 10/24/2023","last_update_posted":"2024-04-19"}]